- -11%
(edit with the Customer Reassurance module)
(edit with the Customer Reassurance module)
(edit with the Customer Reassurance module)
NPP 150 is Dragon Pharma's formulation of injectable Nandrolone Phenylpropionate at 150mg/ml β the original short-ester form of Nandrolone that predates Deca-Durabolin by several years. Each 10ml vial in Dragon Pharma's MCT oil carrier delivers the same anabolic compound as Deca 300, but with a shorter ester that fundamentally changes its cycle dynamics, side effect management and detection window.
Also searched as: NPP 150mg, Nandrolone Phenylpropionate, Durabolin (original), NPP Dragon Pharma.
A fact rarely mentioned in competitor content: Nandrolone Phenylpropionate is not a shorter-ester variant of Deca β it is the original:
The same active compound, fundamentally different pharmacokinetics:
| Parameter | NPP 150 (Phenylpropionate) | Deca 300 (Decanoate) |
|---|---|---|
| Ester | Phenylpropionate | Decanoate |
| Half-life | ~5 days | ~15 days |
| Time to steady-state | ~25 days (5 half-lives) | ~75 days (5 half-lives) |
| Minimum cycle length | 8β10 weeks practical | 14β16 weeks minimum |
| Side effect offset after stopping | ~2β3 weeks | ~6β8 weeks |
| PCT start (after last injection) | ~10β14 days post | ~3β4 weeks post |
| WADA detection window | ~12β18 months | ~18 months+ |
| Injection frequency | Every other day or 3Γ weekly | Weekly or twice weekly |
The detection window data is particularly significant and rarely published clearly in competitor content: despite NPP's shorter half-life, its WADA detection window remains approximately 12-18 months β substantially shorter than Deca's 18+ months, but still among the longest of any AAS. Both compounds produce a nandrolone metabolite (19-norandrosterone) detectable in urine by WADA-accredited laboratories for this extended period.
Three specific advantages over Deca that competitor content rarely articulates clearly: